Skip to content

MK-0518: three-quarters of highly treated patients have undetectable viral load at 24 weeks

Novel NRTI elvucitabine active against HIV in a 7-day monotherapy study

Boosted fosamprenavir and atazanavir show comparable potency, tolerability in treatment-naive

Antibody to CCR5 receptor safe, effective, suitable for weekly dosing, preliminary study shows

Trizivir non-inferior to unboosted atazanavir in treatment-naive

Treatment of acute hepatitis C produces good response rates in HIV-positive patients

HIV/HCV co-infected patients respond to re-treatment with pegylated interferon plus ribavirin

16% of drug-naive entering GSK US studies already have resistance

Nevirapine hepatotoxicity after treatment switch no more likely at higher CD4 counts